What are the common side effects of the rotavirus (Rotavirus Vaccine) vaccine in infants?

Common Side Effects of Rotavirus Vaccine

The rotavirus vaccine is generally well tolerated in infants, with the most common side effects being mild and self-limited, including diarrhea (3% excess), vomiting (1-2% excess), and irritability, while fever rates are similar to placebo. 1

Most Frequent Side Effects in the First 7 Days Post-Vaccination

Based on large-scale ACIP guideline data from over 71,000 infants, the following side effects occur at slightly higher rates than placebo:

Gastrointestinal Symptoms

• Diarrhea: Occurs in 1% excess after dose 1 (10% vs 9% placebo), 3% excess after dose 2 (9% vs 6% placebo), and 3% excess after any dose (18% vs 15% placebo) 1
• Vomiting: Occurs in 2% excess after dose 1 (7% vs 5% placebo) and 2% excess after any dose (12% vs 10% placebo) 1

Other Common Symptoms

• Fever and irritability: Rates are similar between vaccine and placebo recipients during the 7-day period after any dose 1
• Decreased appetite and decreased activity: Reported following the first dose, highly associated with presence of fever 2

Side Effects in the 42-Day Post-Vaccination Period

When monitoring extends to 42 days after vaccination, additional mild symptoms emerge with small but statistically significant increases:

• Vomiting: 1% excess (15% vs 14% placebo) 1, 3
• Diarrhea: 3% excess (24% vs 21% placebo) 1, 3
• Nasopharyngitis: 1% excess (7% vs 6% placebo) 1, 3
• Otitis media: 2% excess (15% vs 13% placebo) 1, 3
• Bronchospasm: 0.4% excess (1.1% vs 0.7% placebo) 1, 3
• Fever: No difference between groups (43% vs 43% placebo) 1, 3

Dose-Specific Patterns

The first dose produces the most noticeable side effects, while subsequent doses are better tolerated. 2

• After the first dose: Fever typically occurs 3-5 days post-administration, along with irritability and decreased appetite 2
• After the second dose: Slight excess of fever >38°C (11% vs 9% placebo, p<0.05) 2
• After the third dose: No increase in symptoms noted 2

Safety in Special Populations

Premature Infants

Rotavirus vaccine is well tolerated in premature infants (25-36 weeks gestational age) with no increased risk of serious adverse events. 1, 3

• Serious adverse event rates are similar between vaccine and placebo groups (5.5% vs 5.8%) 1, 3
• No cases of intussusception reported among preterm infants in large trials 1, 3

Medically Vulnerable Infants

• In infants with high-risk medical conditions, gastrointestinal adverse events are approximately 10% more frequent after rotavirus vaccine 4
• When coadministered with routine vaccines, the adjusted risk ratio for any adverse event is 1.09 (95% CI: 1.05-1.12) 4
• Single administration without other vaccines shows better tolerability with risk ratio of 0.91 (95% CI: 0.81-0.99) 4

Serious Adverse Events

Serious adverse events and deaths occur at similar rates in vaccinated and unvaccinated infants, with no deaths attributed to vaccination. 1

• Overall serious adverse event rate: 2.4% in vaccine group vs 2.6% in placebo group 1
• Death rate: <0.1% in both groups (25 vaccine vs 27 placebo recipients) 1
• Intussusception: No increased risk demonstrated in large trials with 13 cases in vaccine group vs 15 cases in placebo group over 1 year (relative risk 0.9; CI 0.4-1.9) 1

Viral Shedding

Vaccine virus shedding occurs primarily after the first dose but poses minimal transmission risk. 1, 3

• Shedding rates: 8.9% after dose 1,0% after dose 2, and 0.3% after dose 3 1, 3
• Shedding observed as early as 1 day and as late as 15 days after vaccination 1, 3
• Current vaccines have much lower shedding rates than older formulations 5

Important Clinical Caveats

• Do not withhold vaccination for mild gastrointestinal illness, though moderate to severe vomiting or diarrhea warrants delay until resolution 2
• Immunocompromised household contacts should practice good hand hygiene after diaper changes, particularly for 14 days after the first dose, but vaccination of the infant should still proceed as wildtype rotavirus poses greater risk 5, 6
• Do not readminister if infant spits up or regurgitates the dose—simply continue with the remaining scheduled doses 7
• The older RRV-TV vaccine (withdrawn in 1999) had higher rates of fever and reactions than current vaccines (RotaTeq and Rotarix), so older data may overestimate side effects of current formulations 2, 8